
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs is attractive because its lead DR3 antagonist SL-325 has generated strong Phase 1 healthy-volunteer evidence of durable receptor occupancy, a 3.7% ADA rate, and clean safety, which materially de-risks a mechanism that has been hindered by immunogenicity in TL1A-directed peers. The planned Phase 2 RECEPTIVE-CD1 Crohn’s study in 3Q26, the HS expansion later this year, and the SL-846 bispecific and SL-425 programs broaden the pipeline and create multiple shots on goal around a differentiated receptor-focused strategy. Financially, the company ended 2Q26 with $208.3 million in cash, and management expects that to fund operations into 2029, supporting execution without near-term balance-sheet pressure.
Bears say
Shattuck Labs is a high-risk biotech story whose preclinical assets may never advance into clinical studies, leaving SL-325 and related DR3 programs without a clear path to value creation. The competitive backdrop is unfavorable because TL1A has attracted large pharma and multiple biotechs, while established therapies for UC and Crohn’s already exist, forcing Shattuck to prove clear differentiation and eventually build costly commercial infrastructure. Financially, profitability is not expected for several years, and the company will likely need additional capital to fund long development timelines, with no assurance that financing will be available on favorable terms or that its intellectual property will be fully protected.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Shattuck Labs (STTK) Forecast
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares